Deletion of P2 promoter of GJB1 gene a cause of Charcot-Marie-Tooth disease by Kulshrestha, R et al.
1    
 
Deletion of P2 promoter of GJB1 gene a cause of Charcot-Marie-Tooth disease 
1R Kulshrestha, 2S. Burton-Jones, 3T. Antoniadi, 4M Rogers, 5Z. Jaunmuktane, 5S Brandner, 
1N Kiely, 6R. Manuel, 1T Willis 
1. Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry 
2. University Hospital Bristol NHS Trust, Bristol 
3.         West Midlands Molecular Genetics Lab, Birmingham 
4. Cardiff and Vale UHB - Medical Genetics 
5. UCL Institute of Neurology, London 
6.  Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent 
Corresponding author: 
Richa Kulshrestha 
Robert Jones and Agnes Hunt Orthopaedic Hospital 
Gobowen 
Oswestry 
SY10 7AG 
Phone: 01691404378  
Email: richakulshrestha@nhs.net 
 
 
 
2    
 
 
Abstract 
X-linked Charcot-Marie-Tooth disease (CMT) is the second most common cause of CMT, 
and is usually caused by mutations in the gap junction protein beta 1 (GJB1) gene. This gene 
has nerve specific P2 promoter that work synergistically with SOX10 and EGR2 genes to 
initiate transcription. Mutation in this region is known to cause Schwann cell dysfunction. A 
single large family of X linked peripheral neuropathy was identified in our practice. Next 
generation sequencing for targeted panel assay identified an upstream exon-splicing deletion 
identified extending from nucleotide c.-5413 to approximately – c.-49. This matches the 
sequence of 32 nucleotides at positions c.*218-*249 in the 3’UTR downstream of the GJB1 
gene. The deleted fragment included the entire P2 promoter region. The deletion segregated 
with the disease. To our knowledge a deletion of the P2 promoter alone as a cause of CMT 
has not been reported previously.  
Highlights: 
 Report of novel mutation as a cause of CMT. 
 Complete deletion of P2 promoter region of GJB1 gene. 
 Supporting the observation that P2 promoter is central for Schwann cell function. 
Key words: Charcot Marie Tooth disease; X-linked; GJB1; connexin 32; deletion; P2 
promoter; Schwann cell dysfunction. 
Abbreviations: CMT: Charcot–Marie–Tooth; GJB1: gap junction beta 1; CX32: connexin 32; 
SOX10: SRY-Box 10; EGR2: early growth response 2; IPN: inherited peripheral neuropathy; 
NGS: next generation sequencing; 
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1. Introduction 
X linked Charcot–Marie–Tooth (CMT) disease is second most common cause of CMT 
caused by mutation in gap junction beta 1 (GJB1) gene which code for connexin 32 
(CX32).[1] Clinically patients present with distal muscle weakness, wasting and sensory 
loss.[2] The connexin 32 messenger RNA and protein are expressed in Schwann cells in 
peripheral nervous system,[3] confined to Schmidt-Lantermann incisures and paranodal 
segment of nodes of Ranvier.[1] GJB1 gene has nerve tissue specific P2 promoter [4,5] that is 
crucial in initiating transcription.[6] Mutations in the P2 promoter have been reported to 
cause X linked CMT suggesting its impairment leading to Schwann cell dysfunction.[7,8] The 
loss of connexin 32 expression is secondary to failed activation of its promoter by SOX10 and 
EGR2 which work synergistically for GJB1 gene transcription.[9] In this case series we 
report a novel mutation of P2 promoter region of GJB1 gene segregating with the disease. 
2. Patients and Method 
In our practice we identified a large family of X linked inherited peripheral neuropathy with 
unconfirmed molecular genetics. Genomic DNA was extracted from peripheral blood 
according to standard methods. Analysis of 56 genes associated with inherited peripheral 
neuropathy (IPN) was achieved using a custom-designed next generation sequencing (NGS) 
targeted panel assay. Raw data analysis and filtering was performed using a bespoke open-
source pipeline with UCSC hg19 human genome as the reference. Basic copy number 
enumeration was performed using the CONTRA tool as a component of the analysis 
pipeline.[10] Clinical details including onset of symptoms, signs, neurophysiology and 
histology features of affected family members were obtained from the case records with the 
consent of participants for this publication. 
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3. Results 
3.1. Genetics 
In the female index patient no pathogenic sequence variants were detected on testing for 
panel genes including SOX10 and EGR2. However on review, target coverage analysis of the 
gene panel data indicated a possible heterozygous partial deletion in the GJB1 gene region. 
This deletion was evident on MLPA dosage analysis13 using MRC Holland probe mix P405-
A1, which showed abnormal dosage of a single probe, indicating a heterozygous deletion 
within or including the exon 1B (non-coding) region of the GJB1 gene at Xq13.1, and 
corresponding to the P2 promoter. Direct PCR (using primers flanking the deletion break 
points) and Sanger sequence analysis was subsequently used to confirm and characterise this 
deletion further. The identified deletion in the proband removed 5365 nucleotides and 
extends from position c.-5413 (5769 bases upstream of the ATG start codon) to nucleotide c.-
49 (405 bases upstream of the ATG) inclusive. Additionally, a 32 base pair sequence is 
inserted between these break points; a BLAST search [http://blast.ncbi.nlm.nih.gov/Blast.cgi] 
indicated that this matches the sequence of 32 nucleotides at positions c.*218_*249 in the 3’ 
untranslated region, downstream of the GJB1 gene. Sanger sequence analysis has revealed 
that it is likely this sequence is duplicated and inserted between the break points. The deleted 
fragment in this patient (c.-5413_-49) includes the entire P2 promoter (figure 1). This 
deletion is confirmed to be present in all affected family members. 
3.2. Clinical features 
Affected individuals showed clinical evidence of a length dependent peripheral neuropathy. 
Clinical features of affected individuals were variable. They had clawing of toes, feet 
deformity (cavovarus and plano valgus), wasting of small muscles of hand, (figure 2) absent 
reflexes and a glove and stocking distribution of sensory involvement. Clinical features are 
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summarized in table 1. Males had earlier onset of symptoms than females. Neuropathy was 
inherited in X linked dominant fashion with no male-to-male transmission (figure 3). Five 
affected family members had neurophysiology assessment. They had sensorimotor 
demyelinating (four patients) and axonal (one patient) neuropathy. Nerve conduction 
velocities were considerably slowed (< 38 m/sec), suggesting serious demyelinating 
component in four patients (table 2). They did not have central nervous system features hence 
magnetic resonance imaging of brain and spine was not performed. 
3.3. Histology 
The sural nerve biopsy was assessed in one patient by light microscopy and ultrastructuraly 
by electron microscopy (figure 4). Immunohistochemical (IHC) shows prominent loss of 
large myelinated fibres (IHC for myelin basic protein, SMI94 antibody), whilst unmyelinated 
and small myelinated fibres are better preserved (immunostaining for neurofilaments, SMI31 
antibody). Ultrastructural examination highlights the regeneration clusters but shows no signs 
of active macrophage-associated demyelination or chronic demyelinating/re-myelinating 
process. The nerve biopsy excluded inflammation, showed chronic axonal neuropathy with 
no evidence of inflammatory vasculitic process. 
4. Discussion 
GJB1 gene, a common cause of X linked CMT maps to chromosome Xq13.1 and is 10 kb in 
length. This gene encodes 238- aminoacid gap junction, beta 1/connexin 32 protein that is 
involved to form hemichannel connexons as diffusion pathway between Schwann cell 
nucleus and axon.[11] The gene has nerve specific P2 promoter,[4,5] coding region (exon 2) 
and three non-coding exons (1,1A and 1B). Pathogenic mutations are described in both 
coding and non-coding region of the gene (http://www.molgen.ua.ac.be/CMTMutations/). 
Similarly pathogenic variants in P2 promoter region have been reported.[7,8] In our family 
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the deleted fragment (c.-5413_-49) includes the entire P2 promoter region of the gene and 
segregated with the disease. All affected family members have typical features of peripheral 
neuropathy with varying severity suggesting absence of P2 in causing pathogenic nerve 
dysfunction. Male members reported early onset of symptoms. None of the affected 
individuals had hip dysplasia which is an association described with CMT.[11] They did not 
have central nervous involvement as reported with some X linked CMT families.[13,16] 
Electrophysiology was consistent with peripheral nerve dysfunction and nerve biopsy in one 
individual excluded inflammatory cause of neuropathy. 
P2 promoter region is important for gene function as reduced or absent (as in our family) 
activity will cause a reduction/ loss of messenger RNA transcript, hence reduced GJB1 
protein.[9] Functional analysis of promoter region by Houlden et al. (2004) identified its role 
to cause Schwann cell dysfunction by interacting with SOX10 and EGR2 genes.[9] 
Interaction between them is complex. SOX10 and EGR2 bind to the P2 promoter region of 
GJB1 gene at S1-S2 and E2-E3 sites respectively for transcription.[17,18] This interaction 
between GJB1 P2 promoter, SOX10 and EGR2 can be interrupted by either mutations in 
SOX10[19] and EGR2[20] genes or mutation in P2 promoter region of GJB1.[9] Our  patients 
did not have mutations in SOX10 and EGR2 genes supporting restriction of transcription by 
latter mechanism. This observation strengthens the hypothesis by Houlden et al. that P2 
promoter is central in function of Schwann cell in peripheral nerve. 
5. Conclusion 
We have described a novel mutation deleting entire P2 promoter of GJB1 gene in a single 
large family with CMT. Inheritance and phenotype of affected individuals had classical 
features of X linked peripheral neuropathy. This study affirms the role of P2 promoter being 
vital for Schwann cell function. 
7    
 
6. References 
[1] Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-    
Marie-Tooth disease. Science 1993, 262:2039–42. 
[2] Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot–Marie-  
      Tooth disease. Lancet Neurol 2009, 8:654–67. 
[3] Scherer SS, Deschenes SM, Xu YT, et al. Connexin 32 is a myelin- related protein in the     
      PNS and CNS. J Neurosci 1995,15: 8281-94. 
[4] Söhl G, Gillen C, Bosse F, et al. A second alternative transcript of the gap junction gene     
     connexin 32 is expressed in murine Schwann cells and  modulated in injured sciatic nerve.  
     Eur J Cell Biol 1996, 69:267–75. 
[5] Neuhaus IM, Dahl G, Werner R. Use of alternate promoters for tissue-specific expression           
      of the gene coding for connexin 32. Gene 1995,158: 257–62. 
[6] Neuhaus IM, Bone L, Wang S, et al. The human connexion 32     
      gene is transcribed from two tissue specific promotors. Biosci Reports 1996,16: 239- 
      48. 
[7] Murphy SM, Polke J, Manji H, et al. A novel mutation in the nerve-specific 5’UTR of the  
      GJB1 gene causes X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011,  
      16:65-70. 
[8] Tsai PC, Chen CH, Liu AB, et al. Mutation analysis of the 5’non-coding region of GJB1  
8    
 
in a Taiwanese cohort with Charcot-Marie-Tooth neuropathy. J Neurol Sci 2013, 332:51-
5. 
 
[9] Houlden H, Girard M, Cockerell C, et al. Connexin 32 promoter P2 mutations: a  
      mechanism of peripheral nerve dysfunction. Ann Neurol 2004, 56:730–4. 
[10] Li  J, Lupat R, Amarasinghe K, et al. CONTRA: copy number analysis for targeted  
       resequencing. Bioinformatics 2012, 28(10): 1307-13. 
[11] Evans WH. Cell communication across gap junctions: a historical perspective and  
        current developments. Biochem Soc Trans. 2015, 43(3):450-9. 
[12] Bamford NS, White KK, Robinett SA, et al. Neuromuscular hip dysplasia in Charcot- 
        Marie-Tooth disease type 1A. Dev med Child Neurol 2009, 51(5): 408-11. 
[13] Panas M, Kalfakis N, Karadimas C, et al. Episodes of generalized weakness in two sibs  
        with the C164T mutation of the connexion 32 gene. Neurology 2001, 57:1906-8. 
[14] Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous system white matter  
       abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002, 52: 429-34. 
[15] Hanemann CO, Bergmann C, Senderek J, et al. Transient recurrent white matter lesions  
       in X-linked Charcot-Marie-Tooth disease with novel connexion 32 mutation. Arch     
       Neurol, 2003, 60: 605-9. 
[16] Taylor RA, Simon EM, Marks HG, et al. The CNS phenotype of X-linked Charcot- 
        Marie-Tooth disease: more than a peripheral problem. Neurology 2003, 61: 1475-8. 
9    
 
[17] Boundurand N, Girard M, Pingault V, et al. Human Connexin 32, a gap junction protein  
       altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the     
       transcription factor SOX10. Human Mol Genet 2011, 10:2783-95. 
[18] Musso M, Balestra P, Bellone L, et al. The D355V mutation decreases EGR2 binding to  
       an element within the Cx32 promoter. Neurobiol Dis 2001, 8:700-6. 
[19] Inoue K, Tanabe Y, Lupski JR. Myelin deficiencies in both the central and the peripheral  
        nervous system associated with a SOX10 mutation. Ann Neurol 1999, 46:313-8. 
[20] Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2)  
        gene are associated with hereditary myelinopathies. Nat Genet 1998, 18:382-4. 
 
